Compare iShares Core High Dividend ETF (HDV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Core High Dividend ETF trades at $29.05, while State Street SPDR S&P Biotech ETF trades at $159.28. Which is the better fit depends on your goals.
| HDV | XBI | |
|---|---|---|
52-Week High | $29.14 | $164.28 |
52-Week Low | $23.64 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV trades at $28.92, down 0.24% on the day, with a bullish technical signal supported by moving averages. The ETF focuses on high-quality dividend stocks, offering a 3.1% yield and outperforming the S&P 500 year-to-date by 9 percentage points according to 24/7 Wall Street on July 23, 2026. Recent institutional buying includes Bay Colony Advisory Group increasing its position by 370.7% in Q2 2026.
The outlook remains positive for income investors seeking stable dividends from large-cap US companies. Key risks include interest rate sensitivity and sector concentration in defensive stocks. Institutional accumulation and strong technical momentum support continued investor interest in this dividend-focused ETF.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
